Velodrome Study (Protocol number: WR42221)

A 72 weeks study, Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).

ClinicalTrials.gov Identifier: NCT04657289

Principal Investigator: Dr Chen, Fred

For further information about this study, you may visit Clinical Trial Registry:

Or contact the Lions Eye Institute Clinical Trials Office telephone (08) 9381 0750 or email lionsvisiontrials@lei.org.au

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

Request an appointment